Vaccine Study in Guinea-Bissau: What's the Hold-Up?

A vaccine study in Guinea-Bissau, funded by the U.S., is currently on hold. The study aims to compare the health outcomes of newborns who receive the hepatitis B vaccine at birth versus those who get it at six weeks. This has sparked debate among experts.

Uncertain Future

The study's future is uncertain. Guinea-Bissau's public health minister, Quinhin Nantote, mentioned a lack of coordination in making a final decision. Meanwhile, the Africa CDC's director general, Jean Kaseya, emphasized that any decision rests with Guinea-Bissau. The Africa CDC is providing support, but the final call is not theirs to make.

Funding and Criticism

The U.S. CDC awarded a $1.6 million grant for this study. However, critics argue that the study's design and ethical considerations are flawed. They question its relevance to U.S. vaccine policy, especially since the Trump administration recently changed its stance on the hepatitis B vaccine for newborns.

Confusion and Defense

Confusion has surrounded the trial's status. Earlier reports suggested it was canceled, but U.S. officials claimed it was still on track. This week, the Africa CDC defended its role, highlighting its work across the continent and dismissing criticisms as unfounded.

Africa CDC's Stance

Kaseya stressed that the Africa CDC's vision is shaped by African leadership and realities, not Western influence. He also mentioned a recent conversation with U.S. health officials, who denied any criticism of the Africa CDC. Despite the uncertainty, the study's future remains in Guinea-Bissau's hands.